Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

The search for the genetic factors contributing to Alzheimer disease (AD) has evolved
tremendously throughout the years. It started from the discovery of fully penetrant mutations …

Alzheimer's disease (AD) is highly heritable and recent studies have identified over 20
disease-associated genomic loci. Yet these only explain a small proportion of the genetic …

Background Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2
(PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD …

In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for
Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results …

The risk of Alzheimer disease (AD) increases with age, family history and informative genetic
variants. Sadly, there is still no cure or means of prevention. As in other complex diseases …

The global prevalence of dementia has been estimated to be as high as 24 million, and is
predicted to double every 20 years until at least 2040. As the population worldwide …

Alzheimer disease (AD) is the most common causes of neurodegenerative disorder in the
elderly individuals. Clinically, patients initially present with short-term memory loss …

Abstract Alzheimer's disease (AD), manifested by memory loss and a decline in cognitive
functions, is the most prevalent neurodegenerative disease accounting for 60–80% of …

Zebrafish (Danio rerio) have become a powerful tool in neuroscience research due to their
genetic tractability, molecular/physiological conservation, small body size, ease of …